Page 5 - Kronos Bio News Today

Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) was the target of a large drop in short interest during the month of June. As of June 30th, there was short interest totalling 3,330,000 shares, a drop of 21.5% from the June 15th total of 4,240,000 shares. Based on an average trading volume of 420,300 shares, […]

Professor Angela Koehler has been appointed as the faculty director of the MIT Deshpande Center for Technological Innovation. The center works with MIT faculty and students on bringing innovative technologies to market.

Kronos Bio, Inc. (NASDAQ:KRON – Free Report) insider Christopher Dinsmore sold 6,634 shares of Kronos Bio stock in a transaction on Thursday, July 6th. The stock was sold at an average price of $1.75, for a total transaction of $11,609.50. Following the transaction, the insider now directly owns 278,367 shares of the company’s stock, valued […]

Kronos Bio, Inc. (NASDAQ:KRON – Free Report) VP Jorge Dimartino sold 10,818 shares of the firm’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $1.75, for a total value of $18,931.50. Following the completion of the sale, the vice president now directly owns 344,622 shares in […]

Kronos Bio, Inc. (NASDAQ:KRON – Free Report) CFO Yasir B. Al-Wakeel sold 9,617 shares of the stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $1.75, for a total transaction of $16,829.75. Following the completion of the sale, the chief financial officer now directly owns 346,102 shares […]

Kron-20230622 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 2054...

A full dose of lurbinectedin plus a low dose of doxorubicin was clinically active and tolerable in patients with advanced or metastatic soft tissue sarcomas, supporting its continued investigation in those with leiomyosarcoma.

The dynamics of the CDKL5 deficiency disorder market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 -- Kronos Bio, Inc. , a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management... | June 1, 2023

Investigators are aiming to add another agent to the treatment armamentarium for patients with relapsed or refractory solid tumors, as well as those with non-Hodgkin lymphoma, with the development of KB-0742, a CDK9 inhibitor.